Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
Author:
Affiliation:
1. Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA
Publisher
Informa UK Limited
Subject
Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine
Link
https://tandfonline.com/doi/pdf/10.1080/14737159.2016.1181545
Reference148 articles.
1. Global cancer statistics, 2012
2. Non–Small Cell Lung Cancer, Version 6.2015
3. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
4. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer;Science Advances;2023-10-13
2. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer;Beilstein Journal of Nanotechnology;2023-02-22
3. A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer;Journal of Clinical Medicine;2023-01-11
4. Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia;JTO Clinical and Research Reports;2022-03
5. Epidermal growth factor receptor mutations in adenocarcinoma lung: Comparison of techniques for mutation detection;Indian Journal of Pathology and Microbiology;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3